Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, December 24, 2016

New drug could help prevent artery disease in high-risk patients

If you had an ischemic/clot stroke you are already a high risk patient. So ask your doctor where and when this is in production.  A great stroke association would follow this up and get the research done to make it into a translational drug or find out it doesn't work.  At least it would be doing something useful as compared to all the rest of the stroke medical world WAITING ONCE AGAIN FOR SOMEONE ELSE TO SOLVE THE PROBLEM.
.
https://www.mdlinx.com/internal-medicine/top-medical-news/article/2016/12/23/5

University of Missouri School of Medicine News
A recent study by researchers at the University of Missouri School of Medicine has shown that a protein inhibitor drug prevents these blockages, and could be a new therapeutic approach to prevent heart attack, stroke and other diseases caused by blocked blood vessels.
"Arteries are living hoses that narrow and enlarge in order to regulate blood flow to organs and muscles," said William Fay, MD, the J.W. and Lois Winifred Stafford Distinguished Chair in Diabetes and Cardiovascular Research at the MU School of Medicine and senior author of the study. "Smooth muscle cells in the artery regulate blood flow by constricting and relaxing. However, when chronic inflammation occurs in a blood vessel – typically in response to diabetes, high cholesterol and cigarette smoking – the smooth muscle cells in the walls of arteries change their behavior. They gradually accumulate inside the artery and narrow the blood vessel. In the case of coronary arteries, which supply blood to heart muscle cells, this process produces blockages that can lead to a heart attack."

Plasminogen activator inhibitor–1, or PAI–1, is a naturally occurring protein within blood vessels that controls cell migration. With diseases such as diabetes and obesity, PAI–1 over–accumulates in blood vessels. This promotes blockage formation. This process occurs not only in arteries, but also in vein grafts in patients who have undergone coronary artery bypass graft surgery.

Fay's research team studied PAI–039, also known as tiplaxtinin, an investigational drug not yet used to treat humans. The researchers found that PAI–039 inhibited the migration of cultured human coronary artery smooth muscle cells, and prevented the development of blockages in arteries and bypass grafts in mice.

"We found that PAI–039 decreased blockage formation by about 50 percent, which is a powerful effect in the models we used," said Fay, who also serves as a research scientist at the Harry S. Truman Memorial Veterans' Hospital in Columbia, Missouri. "In addition to reducing vascular blockages, inhibiting PAI–1 also produces a blood thinning effect that prevents the blood clots that trigger most heart attacks and strokes."

Fay hopes that if future studies are successful, PAI–039 or similar drugs could be used to prevent blockages in arteries and bypass grafts.

"I don't think there will be any one 'magic pill' that prevents arterial diseases, especially for those with other high–risk conditions," Fay said. "However, perhaps someday a PAI–1 inhibitor can be used in combination with other approaches such as proper diet and exercise, aspirin and cholesterol medications to prevent blood vessel blockages and reduce heart attack and stroke risk."

The study, "Pharmacological Targeting of Plasminogen Activator Inhibitor–1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation," recently was published in the journal Arteriosclerosis, Thrombosis and Vascular Biology.

No comments:

Post a Comment